HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new design immunotoxin for killing high-grade glioma U87 cells: from in vitro to in vivo.

Abstract
A new wave of engineered antibodies, leading to increased effectiveness of functions such as antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity, is being evaluated in clinical settings. Several, such as immunotoxins, are expected to receive approval for usage soon. In this study, using a cognate heavy framework region (HFR2), two complementarity-determining regions (CDRs, i.e., LCDR1 and HCDR3) were fused to the first 388 amino acid residues of diphtheria toxin (DT388) to establish the immunotoxin IT-87. It was found that the mimetics of LCDR1-HFR2-HCDR3 retained the antigen recognition of their parent antibody. The immunotoxin IT-87 could especially kill the U87 MG glioblastoma cell line, the targets of the parent antibody, in vitro; however, the IT-87 could not kill Rajicells. In SCID mice bearing both U87 and Raji cells, the IT-87 directly targeted the U87-induced tumors (via tumor-specific surface markers) and inhibited the growth of the cells in vivo over a 20-day daily IT-87 treatment period. It is believed that the design of this particular immunotoxin could be the basis for even more promising molecules to be used in the treatment of human cancers.
AuthorsZhou Luqiu, Ke Yiquan, Ling Gengqiang, Liu Yijing, Jiang Xiaodan, Cai Yingqian
JournalJournal of immunotoxicology (J Immunotoxicol) 2012 Oct-Dec Vol. 9 Issue 4 Pg. 353-8 ISSN: 1547-6901 [Electronic] England
PMID22458328 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Complementarity Determining Regions
  • Diphtheria Toxin
  • Epitopes
  • IT-87 immunotoxin
  • Immunotoxins
  • Peptide Fragments
  • Recombinant Fusion Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (genetics)
  • Antigens, Neoplasm (immunology)
  • Brain Neoplasms (drug therapy)
  • Cell Line, Tumor
  • Complementarity Determining Regions (genetics)
  • Cytotoxicity, Immunologic
  • Diphtheria Toxin (administration & dosage, genetics)
  • Drug Design
  • Epitopes
  • Glioma (drug therapy)
  • Humans
  • Immunotoxins (administration & dosage, genetics)
  • Mice
  • Mice, SCID
  • Peptide Fragments (genetics)
  • Protein Engineering
  • Recombinant Fusion Proteins (administration & dosage, genetics)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: